Open Access<p>Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer</p>
Author(s) -
Liang Zeng,
YiZhi Li,
Qinqin Xu,
Wenjuan Jiang,
Analyn Lizaso,
Xinru Mao,
Yongchang Zhang,
g Yang,
Zhenxing Wang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s265974
Subject(s) - crizotinib , immunohistochemistry , medicine , concordance , lung cancer , oncology , alk inhibitor , pathology , malignant pleural effusion
Reliable diagnostic approaches to detect ALK rearrangement are critical for selecting patients eligible for crizotinib therapy. This study aimed to compare next-generation sequencing (NGS) and Ventana immunohistochemistry (IHC) in evaluating ALK rearrangements and evaluate their impact on first-line crizotinib efficacy.